DF Gray

5.7k total citations · 3 hit papers
17 papers, 4.5k citations indexed

About

DF Gray is a scholar working on Epidemiology, Hepatology and Infectious Diseases. According to data from OpenAlex, DF Gray has authored 17 papers receiving a total of 4.5k indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Epidemiology, 10 papers in Hepatology and 5 papers in Infectious Diseases. Recurrent topics in DF Gray's work include Hepatitis C virus research (10 papers), Hepatitis B Virus Studies (9 papers) and Liver Disease Diagnosis and Treatment (5 papers). DF Gray is often cited by papers focused on Hepatitis C virus research (10 papers), Hepatitis B Virus Studies (9 papers) and Liver Disease Diagnosis and Treatment (5 papers). DF Gray collaborates with scholars based in United States, United Kingdom and Australia. DF Gray's co-authors include Sally L. Stephenson, Joseph J.�Y. Sung, Yun‐Fan Liaw, Jonathan S. Dixon, Cha‐Ze Lee, Tawesak Tanwandee, Oliver N. Keene, Geoffrey C. Farrell, Wan Cheng Chow and Hon K. Yuen and has published in prestigious journals such as New England Journal of Medicine, Gastroenterology and Journal of Hepatology.

In The Last Decade

DF Gray

17 papers receiving 4.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Lamivudine for Patients with Chronic Hepatitis B and Advanced Liver Disease

2004 1.7k citations Yun‐Fan Liaw, Joseph J.�Y. Sung et al. New England Journal of Medicine profile →
A One-Year Trial of Lamivudine for Chronic Hepatitis B

1998 1.4k citations Ching‐Lung Lai, Rong‐Nan Chien et al. New England Journal of Medicine profile →
Histological outcome during long-term lamivudine therapy

2003 583 citations Jules L. Dienstag, Robert Goldin et al. Gastroenterology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
DF Gray United States	11	4.3k	4.1k	698	105	97	17	4.5k
Flavia Bortolotti Italy	36	4.5k 1.0×	4.3k 1.0×	316 0.5×	93 0.9×	192 2.0×	134	4.8k
Denis Ouzan France	28	2.0k 0.5×	2.1k 0.5×	305 0.4×	58 0.6×	44 0.5×	128	2.4k
Jacqueline C. Melpolder United States	9	2.6k 0.6×	2.9k 0.7×	380 0.5×	66 0.6×	148 1.5×	11	3.4k
Robert Perrillo United States	27	2.4k 0.6×	2.3k 0.5×	364 0.5×	63 0.6×	95 1.0×	60	2.6k
P Dentico Italy	21	1.3k 0.3×	1.1k 0.3×	231 0.3×	107 1.0×	125 1.3×	72	1.7k
Richard Guan Singapore	13	4.0k 0.9×	3.9k 0.9×	821 1.2×	60 0.6×	97 1.0×	18	4.1k
Robert Schvarcz Sweden	24	1.6k 0.4×	1.8k 0.4×	299 0.4×	33 0.3×	73 0.8×	48	2.1k
Enea Spada Italy	26	1.2k 0.3×	1.4k 0.3×	294 0.4×	146 1.4×	65 0.7×	62	1.8k
M. Mizokami Japan	26	2.2k 0.5×	2.3k 0.6×	305 0.4×	84 0.8×	84 0.9×	72	2.7k
Maria de Medina United States	25	1.5k 0.4×	1.5k 0.4×	185 0.3×	61 0.6×	77 0.8×	48	1.9k

Countries citing papers authored by DF Gray

Since Specialization

Citations

This map shows the geographic impact of DF Gray's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by DF Gray with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites DF Gray more than expected).

Fields of papers citing papers by DF Gray

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by DF Gray. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by DF Gray. The network helps show where DF Gray may publish in the future.

Co-authorship network of co-authors of DF Gray

This figure shows the co-authorship network connecting the top 25 collaborators of DF Gray. A scholar is included among the top collaborators of DF Gray based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with DF Gray. DF Gray is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

17 of 17 papers shown

Sung, Joseph J.�Y., Stefan Zeuzem, E. Jenny Heathcote, et al.. (2008). Lamivudine compared with lamivudine and adefovir dipivoxil for the treatment of HBeAg-positive chronic hepatitis B. Journal of Hepatology. 48(5). 728–735. 117 indexed citations

Fleischmann, Roy, Karel Pavelká, Andrew R. Baldassare, et al.. (2006). F.73. Preliminary Efficacy Results of Rituximab (RTX) Following a Repeat Treatment Course in Patients (Pts) with Active Rheumatoid Arthritis (RA). Clinical Immunology. 119. S76–S77. 1 indexed citations

Liaw, Yun‐Fan, Joseph J.�Y. Sung, Wan Cheng Chow, et al.. (2004). Lamivudine for Patients with Chronic Hepatitis B and Advanced Liver Disease. New England Journal of Medicine. 351(15). 1521–1531. 1712 indexed citations breakdown →

Peters, Marion G., Hie‐Won Hann, Paul Martin, et al.. (2003). Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B 1 1The Adefovir Dipivoxil International 461 Study Group includes the following: N. Afdhal (Beth Israel Deaconess Medical Center, Boston, MA); P. Angus (Austin and Repatriation Medical Centre, Melbourne, Australia); Y. Benhamou (Hopital La Pitie Salpetriere, Paris, France); M. Bourliere (Hopital Saint Joseph, Marseille, France); P. Buggisch (Universitaetsklinikum Eppendorf, Department of Medicine, Hamburg, Germany); P. Couzigou (Hopital Haut Leveque, Pessac, France); P. Ducrotte and G. Riachi (Hopital Charles Nicolle, Rouen, France); E. Jenny Heathcote (Toronto Western Hospital, Toronto, Ontario, Canada); H. W. Hann (Jefferson Medical College, Philadelphia, PA); I. Jacobson (New York Presbyterian Hospital, New York, NY); K. Kowdley (University of Washington Hepatology Center, Seattle, WA); P. Marcellin (Hopital Beaujon, Clichy, France); P. Martin (Cedars-Sinai Medical Center, Los Angeles, CA); J. M. Metreau (Centre Hospitalier Universitaire Henri Mondor, Creteil, France); M. G. Peters (University of California, San Francisco, San Francisco, CA); R. Rubin (Piedmont Hospital, Atlanta, GA); S. Sacks (Viridae Clinical Sciences, Inc., Vancouver, Canada); H. Thomas (St. Mary’s Hospital, London, England); C. Trepo (Hopital Hôtel Dieu, Lyon, France); D. Vetter (Hopital Civil, Strasbourg, France); C. L. Brosgart, R. Ebrahimi, J. Fry, C. Gibbs, K. Kleber, J. Rooney, M. Sullivan, P. Vig, C. Westland, M. Wulfsohn, and S. Xiong (Gilead Sciences, Inc., Foster City, CA); D. F. Gray (GlaxoSmithKline, Greenford, Middlesex, England); R. Schilling and V. Ferry (Parexel International, Waltham, MA); and D. Hunt (Covance Laboratories, Princeton, NJ).. Gastroenterology. 126(1). 91–101. 440 indexed citations

Dienstag, Jules L., Robert Goldin, E. Jenny Heathcote, et al.. (2003). Histological outcome during long-term lamivudine therapy. Gastroenterology. 124(1). 105–117. 583 indexed citations breakdown →

Goldin, Robert, et al.. (2001). Knodell and Ishak scoring systems for the assessment of histological changes during lamivudine treatment. Journal of Hepatology. 34. 159–159. 3 indexed citations

Tassopoulos, Nicolaos C., Riccardo Volpes, Giuseppe Pastore, et al.. (1999). Efficacy of lamivudine in patients with hepatitis B e antigen-negative/hepatitis B virus DNA-positive (precore mutant) chronic hepatitis B. European Journal of Gastroenterology & Hepatology. 11(4). 467–467. 22 indexed citations

Lai, Ching‐Lung, Rong‐Nan Chien, Nancy W.Y. Leung, et al.. (1998). A One-Year Trial of Lamivudine for Chronic Hepatitis B. New England Journal of Medicine. 339(2). 61–68. 1427 indexed citations breakdown →

Rizzetto, Mario, P Opolon, Robert Goldin, et al.. (1998). Sustained histologic response is common in the absence of virologic response to interferon (IFN) therapy for chronic hepatitis C (HCV). Gastroenterology. 114. A1291–A1291. 3 indexed citations

10.

Volpes, Riccardo, G Pastore, Jenny Heathcote, et al.. (1998). Lamivudine therapy in patients with anti HBe positive chronic hepatitis B; end of treatment analysis. Journal of Hepatology. 28. 43–43. 7 indexed citations

11.

Heathcote, Jenny, et al.. (1998). Lamivudine and intron a combination treatment in patients with chronic hepatitis B infection. Journal of Hepatology. 28. 43–43. 39 indexed citations

12.

Liaw, Y‐F, et al.. (1998). Two-year lamivudine therapy in chronic hepatitis B infection: Results of a placebo controlled multicentre study in Asia. Gastroenterology. 114. A1289–A1289. 34 indexed citations

13.

Gray, DF, et al.. (1992). The acute phase response in autologous bone marrow transplantation.. PubMed. 23(3-4). 175–93. 9 indexed citations

14.

Cheers, Christina & DF Gray. (1969). Macrophage behaviour during the complaisant phase of murine pertussis.. PubMed. 17(6). 875–87. 51 indexed citations

15.

Gray, DF & Christina Cheers. (1969). The sequence of enhanced cellular activity and protective humoral factors in murine pertussis immunity.. PubMed. 17(6). 889–96. 10 indexed citations

16.

Gray, DF & Christina Cheers. (1967). THE STEADY STATE IN CELLULAR IMMUNITY. Immunology and Cell Biology. 45(4). 407–416. 11 indexed citations

17.

Gray, DF & Christina Cheers. (1967). THE STEADY STATE IN CELLULAR IMMUNITY. Immunology and Cell Biology. 45(4). 417–426. 17 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact